SHIKARI® Q-BEVA


Enzyme immunoassay for the quantitative determination of Bevacizumab (Avastin®) in serum and plasma.

The Matriks Biotek Shikari® Q-BEVA Enzyme Immunoassay has been developed for the quantitative analysis of biologically active form of free bevacizumab®(Avastin®)* in serum and plasma samples.

Serum through levels might be related to predict some clinical outcome during maintenance therapy. It was also possible that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. In this context, identification of biomarkers for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective minimum concentration in order to potentially avoid some side effects with a reliable method might be beneficial.

* AVASTIN® IS A REGISTERED TRADEMARK OF GENENTECH, INC.



Click the diagram to see bigger

about-me





Required Volume (µl) 5
Total Time (min) 70
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 30
Spike Recovery (%) Between 85-115
Shelf Life (year) 1

SHIKARI® S-ATB


Enzyme immunoassay for the quantitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma.

The Matriks Biotek Antibody to Bevacizumab (Avastin®)* Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the quantitative determination of antibodies to Bevacizumab (Avastin) in serum and plasma.

As with all therapeutic proteins, there is a potential for immunogenicity. Accoring to the manufacturers product insert; the incidence of antibody development in patients receiving Avastin has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers. Enzyme-linked immunosorbent assays (ELISAs) were performed on sera from approximately 500 patients treated with Avastin, primarily in combination with chemotherapy. High titer human anti-Avastin antibodies were not detected. Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Avastin with the incidence of antibodies to other products may be misleading. The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures.



Click the diagram to see bigger

about-me




Required Volume (µl) 10
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 30
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
     

PhD Thesis:

  EVALUATION of TRANSSCLERAL PERMEABILITY EFFECTS of NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM in OCULAR DRUG APPLICATIONS
     

PEER REVIEWED JOURNAL ARTICLES:

Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science August 2016 | Volume 7 | Article 1156.**
20  Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica 2015, 667-678.**

** Open Access


   

POSTER PRESENTATIONS:

11  H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. 1553 P, Annals of Oncology, Volume 27, 2016, 7–11 October 2016, Copenhagen, Denmark.

MATRIKS BIOTECHNOLOGY CO., LTD

Gazi Üniversitesi Gölbaşı Yerleşkesi Teknoplaza Binası,
(B Blok Zemin Kat BZ17),
06830,
Gölbaşı/ANKARA/TÜRKİYE

Contact Details

Telephone: +90 (312) 485 42 94
Email: info@matriksbiotek.com
Fax: +90 (312) 485 11 87